Key facts
- Notable investors include China Merchants Capital, China Orient Asset Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Mingbao Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Mingbao Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mingbao Biotechnology
Manufacturer of plant-derived extract products intended for use in food, beverage, and health-product formulation. The company includes the deep processing of tea and natural plants, incorporating primary extraction, refined and advanced processing workflows, customized formulation support, and integrated research-production-trade capabilities developed over more than two decades, enabling domestic and international food, beverage, and nutraceutical markets to obtain consistent ingredient quality, tailored product solutions, and reliable supply for diverse application needs.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Hangzhou, China
- Founded
- 2000
- Employees
- 121
- Website
- mingbaobiotech.com/
- Ownership
- Privately Held (backing)
Mingbao Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mingbao Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mingbao Biotechnology in its N-PORT filings yet. We sweep new filings monthly.